Despite successful medical intervention, people with acromegaly don’t always share their clinician’s optimistic outlook. Eliza B. Geer, MD, director of Memorial Sloan Kettering’s Multidisciplinary Pituitary & Skull Base Tumor Center, takes us through a holistic approach to treating this often-confounding condition and how a team-based methodology is frequently the key to success. Recently, I was...
Always mystifying and bit mysterious, the pituitary is the gland that sends out the orders to the other glands in the body, from regulating the adrenals and the thyroid to coordinating reproduction. However, thanks to a worldwide collaboration and a new database, this “master gland” is slowly but surely unlocking its secrets. The pituitary –...
Positive results from the Phase III LINC 4 study have confirmed the efficacy and safety of osilodrostat, an oral therapy for patients with Cushing’s disease. The results were published in The Journal of Clinical Endocrinology & Metabolism. Recordati Rare Diseases is marketing the drug as ISTURISA®. The LINC 4 study augments the efficacy and safety...
Since acromegaly is such a rare disorder, when an endocrinologist is presented with a potential case, the most accurate and complete data available would be a helpful tool. Endocrine News takes a closer look at how the Mexican Acromegaly Registry has helped endocrinologists address the issues patients with acromegaly face, both physically and financially. ...
Radiographic arthropathy progresses significantly in patients with long-term, well-controlled acromegaly, according to a study recently published in The Journal of Clinical Endocrinology & Metabolism. Researchers led by Iris C. M. Pelsma, MD, MSc, of Leiden University Medical Center in The Netherlands, point out that one of the long-term complications of acromegaly is acromegalic arthropathy, which...
Data presented last month at ENDO 2021 from Phase 3 of the MPOWERED study showed that oral octreotide capsules improved clinical symptoms and other patient-reported outcomes compared to long-acting injectable somatostatin receptor ligands (iSRLs) in patients with acromegaly. In addition, oral octreotide capsules met the pre-specified non-inferiority margin compared to long-acting iSRLs in maintenance of...
Tumor size and random growth hormone concentration at diagnosis are the best predictors for remission of acromegaly after transsphenoidal surgery (TSS), according to a study recently published in The Journal of Clinical Endocrinology & Metabolism. Researchers led by Eva C. Coopmans, MD, of Erasmus University Medical Center in Rotterdam, The Netherlands, point out that TSS...
Machine learning (ML), a type of artificial intelligence, could be used to predict how patients with acromegaly respond to first-generation somatostatin receptor ligands (fg-SRLs), according a study recently published in The Journal of Clinical Endocrinology & Metabolism. Researchers led by Mônica Gadelha, MD, PhD, of the Endocrine Unit and Neuroendocrinology Research Center at the Medical...
Despite successful medical intervention, people with acromegaly don’t always share their clinician’s optimistic outlook. Eliza B. Geer, MD, director of Memorial Sloan Kettering’s Multidisciplinary Pituitary & Skull Base Tumor Center, takes us through a holistic approach to treating this often-confounding condition and how a team-based methodology is frequently the key to success. Recently, I was...
